Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer.

Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C.

Cell Stem Cell. 2007 Sep 13;1(3):313-23. doi: 10.1016/j.stem.2007.06.002.

2.

CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients.

Zhang SS, Han ZP, Jing YY, Tao SF, Li TJ, Wang H, Wang Y, Li R, Yang Y, Zhao X, Xu XD, Yu ED, Rui YC, Liu HJ, Zhang L, Wei LX.

BMC Med. 2012 Aug 7;10:85. doi: 10.1186/1741-7015-10-85.

3.

ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.

Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE.

PLoS One. 2011;6(6):e20636. doi: 10.1371/journal.pone.0020636. Epub 2011 Jun 13.

4.

Cancer stem cells and tumor metastasis: first steps into uncharted territory.

Dalerba P, Clarke MF.

Cell Stem Cell. 2007 Sep 13;1(3):241-2. doi: 10.1016/j.stem.2007.08.012.

5.

Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1α-dependent manner in pancreatic cancer cells.

Hashimoto O, Shimizu K, Semba S, Chiba S, Ku Y, Yokozaki H, Hori Y.

Pathobiology. 2011;78(4):181-92. doi: 10.1159/000325538. Epub 2011 Jul 19.

6.

CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide.

Banerjee S, Nomura A, Sangwan V, Chugh R, Dudeja V, Vickers SM, Saluja A.

Clin Cancer Res. 2014 May 1;20(9):2388-99. doi: 10.1158/1078-0432.CCR-13-2947. Epub 2014 Mar 14.

7.

Upregulation of autophagy by hypoxia-inducible factor-1α promotes EMT and metastatic ability of CD133+ pancreatic cancer stem-like cells during intermittent hypoxia.

Zhu H, Wang D, Zhang L, Xie X, Wu Y, Liu Y, Shao G, Su Z.

Oncol Rep. 2014 Sep;32(3):935-42. doi: 10.3892/or.2014.3298. Epub 2014 Jul 2.

PMID:
24994549
8.

The utility of hyperthermic intra-abdominal chemotherapy with gemcitabine for the inhibition of tumor progression in an experimental model of pancreatic peritoneal carcinomatosis, in relation to their behavior with pancreatic cancer stem cells CD133+ CXCR4.

García-Santos EP, Padilla-Valverde D, Villarejo-Campos P, Murillo-Lázaro C, Fernández-Grande E, Palomino-Muñoz T, Rodríguez-Martínez M, Amo-Salas M, Nuñez-Guerrero P, Sánchez-García S, Puerto-Puerto A, Martín-Fernández J.

Pancreatology. 2016 Jul-Aug;16(4):632-9. doi: 10.1016/j.pan.2016.04.031. Epub 2016 May 12.

PMID:
27289344
9.

Minnelide effectively eliminates CD133(+) side population in pancreatic cancer.

Nomura A, McGinn O, Dudeja V, Sangwan V, Saluja AK, Banerjee S.

Mol Cancer. 2015 Nov 23;14:200. doi: 10.1186/s12943-015-0470-6.

10.

Identification of a novel subpopulation of tumor-initiating cells from gemcitabine-resistant pancreatic ductal adenocarcinoma patients.

Shimizu K, Chiba S, Hori Y.

PLoS One. 2013 Nov 21;8(11):e81283. doi: 10.1371/journal.pone.0081283. eCollection 2013.

11.

Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens.

Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S, Rhim JS.

Cancer Res. 2007 Apr 1;67(7):3153-61.

12.

Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM- Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis.

Bertolini G, D'Amico L, Moro M, Landoni E, Perego P, Miceli R, Gatti L, Andriani F, Wong D, Caserini R, Tortoreto M, Milione M, Ferracini R, Mariani L, Pastorino U, Roato I, Sozzi G, Roz L.

Cancer Res. 2015 Sep 1;75(17):3636-49. doi: 10.1158/0008-5472.CAN-14-3781. Epub 2015 Jul 3.

13.

CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche.

Kim M, Koh YJ, Kim KE, Koh BI, Nam DH, Alitalo K, Kim I, Koh GY.

Cancer Res. 2010 Dec 15;70(24):10411-21. doi: 10.1158/0008-5472.CAN-10-2591. Epub 2010 Nov 5.

14.

The critical roles of tumor-initiating cells and the lymph node stromal microenvironment in human colorectal cancer extranodal metastasis using a unique humanized orthotopic mouse model.

Margolin DA, Myers T, Zhang X, Bertoni DM, Reuter BA, Obokhare I, Borgovan T, Grimes C, Green H, Driscoll T, Lee CG, Davis NK, Li L.

FASEB J. 2015 Aug;29(8):3571-81. doi: 10.1096/fj.14-268938. Epub 2015 May 11.

PMID:
25962655
15.
16.

Highly lymphatic metastatic pancreatic cancer cells possess stem cell-like properties.

Luo G, Long J, Cui X, Xiao Z, Liu Z, Shi S, Liu L, Liu C, Xu J, Li M, Yu X.

Int J Oncol. 2013 Mar;42(3):979-84. doi: 10.3892/ijo.2013.1780. Epub 2013 Jan 18.

PMID:
23338123
17.

Interferon-alpha modulates the chemosensitivity of CD133-expressing pancreatic cancer cells to gemcitabine.

Hayashi T, Ding Q, Kuwahata T, Maeda K, Miyazaki Y, Matsubara S, Obara T, Natsugoe S, Takao S.

Cancer Sci. 2012 May;103(5):889-96. doi: 10.1111/j.1349-7006.2012.02235.x. Epub 2012 Mar 13.

18.

Pancreatic cancer stem cells: their role in pancreatic cancer patient outcomes and what is future?

Habib M, Saif MW.

JOP. 2013 Jul 10;14(4):401-4. doi: 10.6092/1590-8577/1658. Review.

19.

CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer.

Nomura A, Banerjee S, Chugh R, Dudeja V, Yamamoto M, Vickers SM, Saluja AK.

Oncotarget. 2015 Apr 10;6(10):8313-22.

20.

Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.

Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, Ellwart JW, Mustafa M, Bartenstein P, D'Haese JG, Schoenberg MH, Berger F, Jauch KW, Hidalgo M, Heeschen C.

Gastroenterology. 2009 Sep;137(3):1102-13. doi: 10.1053/j.gastro.2009.05.053. Epub 2009 Jun 6.

PMID:
19501590

Supplemental Content

Support Center